Dividend Growth Split Corp. Announces Extension of Term

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
56
Dividend Growth Split Corp. Announces Extension of Term and Preferred Share Distribution Rate

TORONTO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- (TSX: DGS, DGS.PR.A) As previously announced,  the board of directors of Dividend Growth Split Corp.   (the “Fund”) extended the maturity date of the class A and preferred shares of the Company for a period of up to five years beyond the current maturity date of November 28, 2019.  The board of directors is pleased to announce that the new term of the Fund will be to September 27, 2024.   In addition, the Fund announces that the distribution rate for the preferred shares (the “Preferred Shares”) for the new term from November 29, 2019 to September 27, 2024 has been increased to $0.55 per Preferred Share per annum (5.5% on the original issue price of $10) payable quarterly.  The Preferred Share distribution rate is based on current market rates for preferred shares with similar terms. 

The term extension offers preferred shareholders the opportunity to enjoy preferential cash dividends until September 27, 2024.  Since inception in December 2007 to August 31, 2019, the Preferred Share has delivered a 5.4% (1) per annum return.  In addition, the Fund intends to maintain the targeted monthly Class A Share distribution rate of at least $0.10 per Class A Share when the net asset value per unit (consisting of one Class A Share and one Preferred Share) is greater than $15.00, after taking into consideration the payment of the Class A Share distribution. 

Since inception in December 2007 to August 31, 2019, the Class A share has delivered a 7.4% (1) per annum return, which outperformed the S&P/TSX Composite Index by 2.8% per annum.  Since inception to August 31, 2019, Class A shareholders have received cash distributions of $12.89.  Class A shareholders also have the option to reinvest their cash distributions in a dividend reinvestment plan which is commission free to participants.  Class A shareholders can enroll in the DRIP program by contacting their investment advisor.

The Fund invests, on an approximately equally-weighted basis, in a portfolio consisting primarily of equity securities of Canadian dividend growth companies.  In addition, DGS may hold up to 20% of the total assets of the portfolio in global dividend growth companies for diversification and enhanced return potential. 

In connection with the extension, shareholders who do not wish to continue their investment in the Fund, may retract their Preferred Shares and Class A Shares on November 28, 2019 pursuant to a special retraction right and receive a retraction price that is calculated in the same way that such price would be calculated if the Fund were to terminate on November 28, 2019.  Pursuant to this option, the retraction price may be less than the market price if the security is trading at a premium to net asset value.  Notice must be provided to your investment dealer by October 31, 2019 at 5:00 p.m. (Toronto time) in order to exercise this right; however, investment dealers may have earlier deadlines.  Alternatively, shareholders may sell their shares through their securities dealer for the market price at any time, potentially at a higher price than would be achieved through retraction, or shareholders may take no action and continue to hold their shares.

About Brompton Funds

Brompton Funds, a division of Brompton Group which was founded in 2000, is an experienced investment fund manager with over $2 billion in assets under management. Brompton’s investment solutions include TSX closed-end funds and exchange-traded funds.  For further information, please contact your investment advisor, call Brompton’s investor relations line at 416-642-6000 (toll-free at 1-866-642-6001), email info@bromptongroup.com or visit our website at www.bromptongroup.com .

(1) Annual Compound Returns   1-Year     3-Year   5-Year   10-Year   Since Inception (2)  
Dividend Growth Split Corp. – Class A 7.3%   9.8%   4.7%   13.0%   7.4%  
S&P/TSX Composite Index 4.3%   7.2%   4.1%   7.3%   4.6%  
Dividend Growth Split Corp. – Preferred 5.4%   5.4%   5.4%   5.4%   5.4%  
S&P/TSX Preferred Share Index (13.5%)   2.0%   (1.6%)   1.6%   1.7%  

(2) Period from December 3, 2007 (commencement of operations) to August 31, 2019.

Returns are for the periods ended August 31, 2019.  The table shows the Fund’s compound return on a Class A share and Preferred share for each period indicated, compared with the S&P/TSX Composite Index (‘‘Composite Index’’) and the S&P Preferred Share Index (“Preferred Index”). The Composite Index tracks the performance of a broad index of large-capitalization issuers listed on the Toronto Stock Exchange. The Preferred Index is comprised of preferred shares listed and trading on the Toronto Stock Exchange that meet criteria relating to size, liquidity and issuer rating.  The Fund invests in a passively managed portfolio of companies that is rebalanced at least annually. It is therefore not expected the Company’s performance will mirror that of the Composite Index, which has a more diversified portfolio. The Composite Index is calculated without the deduction of management fees, fund expenses and trading commissions, whereas the performance of the Company’s performance is calculated after deducting such fees and expenses.  Further, the performance of the Fund’s Class A shares is impacted by the leverage provided by the Fund’s Preferred shares. 

You will usually pay brokerage fees to your dealer if you purchase or sell shares of the investment funds on the Toronto Stock Exchange or other alternative Canadian trading system (an “exchange”).  If the shares are purchased or sold on an exchange, investors may pay more than the current net asset value when buying shares of the investment fund and may receive less than the current net asset value when selling them.

There are ongoing fees and expenses associated with owning shares of an investment fund.  An investment fund must prepare disclosure documents that contain key information about the fund.  You can find more detailed information about the Fund in the public filings available at www.sedar.com.  The indicated rates of return are the historical annual compounded total returns including changes in share value and reinvestment of all distributions and do not take into account certain fees such as redemption costs or income taxes payable by any securityholder that would have reduced returns.  Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated.

Certain statements contained in this document constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed in this document and to other matters identified in public filings relating to the Fund, to the future outlook of the Fund and anticipated events or results and may include statements regarding the future financial performance of the Fund. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information.  Investors should not place undue reliance on forward-looking statements.  These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

ING's Successful Share Buyback and New €1.6 Billion Plan

Updated Category News Views 246

ING Finalizes Share Buyback and Unveils New Distribution Strategy Recently, ING announced that it has successfully completed its comprehensive share buyback program. This initiative, which commenced earlier, concluded with the repurchase of an impressive total of 101,193,469 ordinary shares at an average price of €19.77, resulting in a total expenditure of approximately...

Continue Reading
Aicuris' Pritelivir Shows Promise for Immunocompromised Patients

Updated Category News Views 203

Breakthrough Results for Pritelivir in Immunocompromised Patients Pritelivir has distinguished itself in the realm of treatment for refractory Herpes Simplex Virus (HSV) infections among immunocompromised patients. The recent Phase 3 trial reported a statistically significant superiority in lesion healing compared to standard-of-care treatments, demonstrating the...

Continue Reading
Market Insights: Bitcoin's Stability Amidst Altcoin Declines

Updated Category News Views 213

Market Dynamics: Bitcoin Stands Firm as Altcoins Dwindle In a recent turn of events, leading altcoins such as Ethereum and XRP experienced significant price drops, indicating a potential shift in the cryptocurrency market's dynamics. This selloff occurred after a period of robust growth within the broader market, shaking investor confidence. Understanding the Market...

Continue Reading
American Rebel Holdings Partners with Ace Distributing in PA

Updated Category News Views 164

American Rebel Holdings Strengthens Beer Distribution Network Ace Distributing, a prestigious beer wholesaler with a rich history, has joined the American Rebel Light Beer family. This partnership marks a significant step in American Rebel's strategy to enhance its distribution network across Pennsylvania. The Partnership Breakdown American Rebel Holdings, Inc. (NASDAQ:...

Continue Reading
Core Natural Resources Delivers Strong Q3 Performance Insights

Updated Category News Views 143

Core Natural Resources Achieves Impressive Q3 Results Core Natural Resources, Inc. (NYSE: CNR) has just reported an exciting fiscal performance for its third quarter, showcasing substantial growth in net cash generated from operating activities and increased shareholder returns. Strong Financial Milestones The company generated net cash provided by operating activities...

Continue Reading